Kamal S. Pohar

Urology
300 W 10th Ave
Columbus, OH 43210

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer.

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 15, 2025

Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.

Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.

Journal: European urology
Published: October 22, 2025

T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancer.

T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancer.

Journal: Journal for immunotherapy of cancer
Published: September 07, 2025

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.

Journal: The New England journal of medicine
Published: November 26, 2024

Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.

Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.

Journal: European urology
Published: May 01, 2024

Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry.

Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry.

Journal: Cancers
Published: March 06, 2024

Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.

Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.

Journal: Translational cancer research
Published: January 26, 2024

Roles of Androgen Receptor Signaling in Urothelial Carcinoma.

Roles of Androgen Receptor Signaling in Urothelial Carcinoma.

Journal: Cancers
Published: January 15, 2024

Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.

Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.

Journal: Bladder cancer (Amsterdam, Netherlands)
Published: July 27, 2023

Interruptions in bladder cancer care during the COVID-19 public health emergency.

Interruptions in bladder cancer care during the COVID-19 public health emergency.

Journal: Urologic oncology
Published: July 25, 2023

Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients' access to novel therapeutics.

Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients' access to novel therapeutics.

Journal: Urologic oncology
Published: December 11, 2022

Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light?

Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light?

Journal: Urologic oncology
Published: August 19, 2022
Showing 1-12 of 48

Last Updated: 09/26/2026